All In Biotech

BLA 761054 · Samsung Bioepis CO LTD

Renflexis

Infliximab-Abda · Injection · Tumor Necrosis Factor Blocker

Last checked: Nov 20, 2026Latest source record: Oct 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Apr 21, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

379

125 Phase 3, 45 recruiting

FAERS reports

61,715

59,686 serious, 7,134 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. ( 5.1 ) Discontinue RENFLEXIS if a patient develops a serious infection. Perform test for latent TB; if positive, start treatment for TB prior to starting RENFLEXIS. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. ( 5.2 ) Postmarketing cases of fatal hepatosplenic T-cell lymphoma...

What it is approved for

From the label in effect Aug 28, 2026.

RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: reducing signs and symptoms in adult patients with active disease. ( 1.6 ) Psoriatic Arthritis: reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. ( 1.7 ) Plaque Psoriasis: treatment of...

Mechanism: Infliximab products neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit binding of TNFα with its receptors. Infliximab products do not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα. Biological activities attributed to TNFα include: induction of pro-inflammatory cytokines such as interleukins (IL) 1 and 6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, activation...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • RENFLEXIS · INFLIXIMAB-ABDA 100MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Infliximab" as an intervention, any sponsor and status, largest first.

All 379 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use21,242
  • condition aggravated13,192
  • drug ineffective12,511
  • intentional product use issue10,146
  • arthralgia8,428
  • fatigue6,811
  • pain6,480
  • inappropriate schedule of product administration5,922
  • nausea5,656
  • weight increased5,605
  • headache5,467
  • malaise5,372

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004271
2005759
2006337
2007524
2008480
2009722
2010478
2011404
2012786
2013258
2014260
2015387
2016570
2017882
20181,692
20193,614
20205,586
20214,852
20228,535
20238,837
20247,418
20258,932
20265,119

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Renflexis (Infliximab-Abda)

2024 spending

$7.6M

Beneficiaries

392

1,899 claims

Per beneficiary

$19,387

$696.65 per unit

View as table
YearSpending
2020$2,742,064
2021$4,849,304
2022$5,531,305
2023$6,533,060
2024$7,599,664

Part B: Renflexis (Infliximab-Abda) · HCPCS Q5104

2024 spending

$63.9M

Beneficiaries

8,121

42,914 claims

Per beneficiary

$7,865

2024 ASP limit $29.79 per unit

View as table
YearSpending
2020$49,286,216
2021$51,022,400
2022$88,546,141
2023$87,091,963
2024$63,867,860

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,993 on PubMed

Sponsor: Samsung Bioepis CO LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.